CareDx Activities at American Society for Histocompatibility & Immunogenetics

CareDx, Inc. CDNA, a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, will highlight CareDx's Olerup pre-transplant diagnostic products at the 43rd Annual American Society for Histocompatibility & Immunogenetics (ASHI) which takes place September 11-15, 2017 in San Francisco, CA.

Brisbane, California (PRWEB) September 11, 2017

CareDx, Inc. CDNA, a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, will highlight CareDx's Olerup pre-transplant diagnostic products at the 43rd Annual American Society for Histocompatibility & Immunogenetics (ASHI) which takes place September 11-15, 2017 in San Francisco, CA.

News for Olerup product portfolio at the meeting includes:

• Olerup QTYPE Speed and precision in HLA typing available on Roche LightCycler 480II, with additional platforms under development. Rapid typing is vital for deceased donor transplantation.
• Olerup SSP Continued HLA foundational typing with timely updates for new HLA alleles.
• Olerup SBT™ Accurate, gold standard sequence based typing (SBT) including reagents for sequencing, HARPS and software (Olerup Assign™ SBT). The SBT technology sets the benchmark for high-resolution HLA typing.
• CareDx will also host a symposium on September 12, 12:00–2:00 pm including presentations titled "QTYPE: Advancements in Rapid HLA Typing" Bruno Vanherberghen, PhD, Technical Brand Manager at CareDx. "Non-Invasive Rejection Monitoring for Thoracic Transplantation" Kiran K. Khush, MD, MAS, Associate Professor of Medicine, Stanford University; and "Clinical Utility of AlloSure, a Donor-Derived Cell-Free DNA test Validated in Kidney Transplantation" Robert N. Woodward, Ph.D., Senior Director, R&D at CareDx.

Abstract 419 (Poster P156) with co-authors from Children's Hospital of Oakland Research Institute, Cornell University and Stanford University compares the HLA antigenic and immunogenic mismatches of transplant recipients and donors in a lung transplant study. Abstract 433 (Poster P140) indicates that the degree of HLA mismatch between donor and recipient does not confound measurement of donor-derived cell-free DNA (AlloSure).

The CareDx booth (#100) will highlight key innovations with a video on Olerup QTYPE and a demonstration of SCORE 6, the recently developed software for the QTYPE 11 product.

"The annual ASHI meeting highlights scientific and medical advances in the fundamental understanding of transplantation as well as the unique collaborative and data sharing nature of the transplant community," said John Sninsky, Chief Scientific Officer at CareDx. "CareDx is proud to be among the stakeholders committed to developing and improving solutions to augment clinical decisions at critical stages along the transplant care continuum. Only with the delivery of precision care will adverse outcomes and graft loss be reduced."

About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure® for post-transplant surveillance and Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA typing.
For more information, please visit: http://www.CareDx.com.

Forward Looking Statements
This press release contains forward-looking statements about our business, research, development and commercialization efforts. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks associated with successful research, development and planned commercialization of our technologies, that are described in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2016 filed by us with the SEC on April 21, 2017 and any periodic reports that we have subsequently filed with the SEC. Any of these may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

For the original version on PRWeb visit: http://www.prweb.com/releases/2017/09/prweb14679266.htm